Umbilical cord mesenchymal stem cell therapy - Alliancells Bioscience

Drug Profile

Umbilical cord mesenchymal stem cell therapy - Alliancells Bioscience

Alternative Names: UC-MSC - Alliancells Bioscience

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Alliancells Bioscience
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Liver cirrhosis; Rheumatoid arthritis

Most Recent Events

  • 16 Feb 2016 No development reported - Phase-I/II for Cirrhosis in China (IV)
  • 14 Apr 2015 No development reported - Phase-I/II for Rheumatoid arthritis in China (IV)
  • 01 Jul 2014 Phase-I/II clinical trials in Cirrhosis in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top